title: Paediatric Fabry disease.
abstract: Fabry disease is a rare, progressive X-linked inborn error of the glycosphingolipid metabolic pathway. Mutations of the GLA gene result in deficiency of the lysosomal enzyme, α-galactosidase A (α-Gal A) with accumulation of glycosphingolipids, particularly globotriaosylceramide (GL3) in the vascular endothelium of various tissues. Accumulation of GL3 eventually leads to life threatening renal, cardiac and cerebrovascular complications typically in the third to fifth decades of life. The first signs and symptoms of classic Fabry disease however appear in childhood but diagnosis is often delayed. The symptoms most commonly experienced in childhood include neuropathic pain, gastrointestinal dysfunction, hyperhidrosis and heat intolerance. Timely diagnosis is important as early treatment with enzyme replacement therapy reduces GL3 accumulation, can stabilize disease progression and potentially prevent irreversible organ damage. Physicians should be familiar with the signs and symptoms of Fabry disease in childhood and be particularly vigilant for unusual or non-specific but recurrent or episodic symptoms.
authors.affiliation: Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney Children's Hospital Network, Sydney, NSW, Australia.
authors.forename: Carolyn
authors.initials: C
authors.lastname: Ellaway
keywords: Fabry disease; acroparaesthesia; paediatric; α-galactosidase
references.citation: J Neurol Sci. 2014 Sep 15;344(1-2):5-19
references.pmid: 25106696
references.citation: J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S150-3
references.pmid: 12068029
references.citation: J Inherit Metab Dis. 2006 Feb;29(1):106-11
references.pmid: 16601876
references.citation: Acta Ophthalmol (Copenh). 1984 Dec;62(6):923-31
references.pmid: 6098121
references.citation: QJM. 2010 Sep;103(9):641-59
references.pmid: 20660166
references.citation: Ther Clin Risk Manag. 2011;7:69-82
references.pmid: 21445281
references.citation: J Pediatr. 2005 Jul;147(1):102-5
references.pmid: 16027705
references.citation: BMC Neurol. 2011 May 27;11:61
references.pmid: 21619592
references.citation: Acta Paediatr. 2008 Apr;97(4):463-9
references.pmid: 18363956
references.citation: J Am Soc Nephrol. 2013 Jan;24(1):137-48
references.pmid: 23274955
references.citation: Drug Des Devel Ther. 2011 Mar 14;5:155-73
references.pmid: 21552486
references.citation: Genet Med. 2015 May;17(5):323-30
references.pmid: 25232851
references.citation: Genet Mol Biol. 2012 Dec;35(4 (suppl)):947-54
references.pmid: 23413206
references.citation: Pediatr Res. 2008 Nov;64(5):550-5
references.pmid: 18596579
references.citation: Clin Genet. 2012 May;81(5):485-90
references.pmid: 21457233
references.citation: Ann Intern Med. 2007 Jan 16;146(2):77-86
references.pmid: 17179052
references.citation: Acta Paediatr. 2006 Jan;95(1):86-92
references.pmid: 16498740
references.citation: Mol Genet Metab. 2013 Jun;109(2):201-7
references.pmid: 23566439
references.citation: Pediatr Nephrol. 2013 May;28(5):679-87
references.pmid: 22898981
references.citation: Clin Genet. 2013 May;83(5):432-8
references.pmid: 22880956
references.citation: Am J Kidney Dis. 2008 May;51(5):767-76
references.pmid: 18436087
references.citation: Br J Ophthalmol. 2007 Feb;91(2):210-4
references.pmid: 16973664